An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans
Cannabis is the most commonly used illicit substance worldwide. Recent years have seen an increase in cannabis consumption, and with new approvals and therapeutic indications, there are challenges in minimizing the risks and interactions between cannabis-based products, cannabis prescription drugs,...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/3/319 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850091334614908928 |
|---|---|
| author | Dolly Andrea Caicedo Clara Pérez-Mañá Magí Farré Esther Papaseit |
| author_facet | Dolly Andrea Caicedo Clara Pérez-Mañá Magí Farré Esther Papaseit |
| author_sort | Dolly Andrea Caicedo |
| collection | DOAJ |
| description | Cannabis is the most commonly used illicit substance worldwide. Recent years have seen an increase in cannabis consumption, and with new approvals and therapeutic indications, there are challenges in minimizing the risks and interactions between cannabis-based products, cannabis prescription drugs, other approved prescription drugs, and other substances of abuse. Thus, identifying the enzymes metabolizing cannabinoid drugs and their relationship with other prescription drugs is crucial for understanding the potential interactions and effects of their simultaneous use. This article offers a comprehensive review of cannabis and the pharmacokinetic interactions between cannabis products, cannabis prescription drugs, and other approved prescription drugs, as well as other substances of abuse. It also compiles existing evidence of these interactions and describes the clinical outcomes associated with the inhibition or induction of various enzymes. |
| format | Article |
| id | doaj-art-03e8408f8573433db70011c8d0de3501 |
| institution | DOAJ |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-03e8408f8573433db70011c8d0de35012025-08-20T02:42:24ZengMDPI AGPharmaceutics1999-49232025-03-0117331910.3390/pharmaceutics17030319An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in HumansDolly Andrea Caicedo0Clara Pérez-Mañá1Magí Farré2Esther Papaseit3Department of Clinical Pharmacology, Hospital Universitari Germans Trias I Pujol, Institut de Recerca Germans Trias i Pujol (IGTP), Carretera de Canyet, s/n, 08916 Badalona, SpainDepartment of Clinical Pharmacology, Hospital Universitari Germans Trias I Pujol, Institut de Recerca Germans Trias i Pujol (IGTP), Carretera de Canyet, s/n, 08916 Badalona, SpainDepartment of Clinical Pharmacology, Hospital Universitari Germans Trias I Pujol, Institut de Recerca Germans Trias i Pujol (IGTP), Carretera de Canyet, s/n, 08916 Badalona, SpainDepartment of Clinical Pharmacology, Hospital Universitari Germans Trias I Pujol, Institut de Recerca Germans Trias i Pujol (IGTP), Carretera de Canyet, s/n, 08916 Badalona, SpainCannabis is the most commonly used illicit substance worldwide. Recent years have seen an increase in cannabis consumption, and with new approvals and therapeutic indications, there are challenges in minimizing the risks and interactions between cannabis-based products, cannabis prescription drugs, other approved prescription drugs, and other substances of abuse. Thus, identifying the enzymes metabolizing cannabinoid drugs and their relationship with other prescription drugs is crucial for understanding the potential interactions and effects of their simultaneous use. This article offers a comprehensive review of cannabis and the pharmacokinetic interactions between cannabis products, cannabis prescription drugs, and other approved prescription drugs, as well as other substances of abuse. It also compiles existing evidence of these interactions and describes the clinical outcomes associated with the inhibition or induction of various enzymes.https://www.mdpi.com/1999-4923/17/3/319cannabistetrahydrocannabinolTHCcannabidiolCBDdrug interactions |
| spellingShingle | Dolly Andrea Caicedo Clara Pérez-Mañá Magí Farré Esther Papaseit An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans Pharmaceutics cannabis tetrahydrocannabinol THC cannabidiol CBD drug interactions |
| title | An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans |
| title_full | An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans |
| title_fullStr | An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans |
| title_full_unstemmed | An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans |
| title_short | An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans |
| title_sort | overview of the potential for pharmacokinetic interactions between drugs and cannabis products in humans |
| topic | cannabis tetrahydrocannabinol THC cannabidiol CBD drug interactions |
| url | https://www.mdpi.com/1999-4923/17/3/319 |
| work_keys_str_mv | AT dollyandreacaicedo anoverviewofthepotentialforpharmacokineticinteractionsbetweendrugsandcannabisproductsinhumans AT claraperezmana anoverviewofthepotentialforpharmacokineticinteractionsbetweendrugsandcannabisproductsinhumans AT magifarre anoverviewofthepotentialforpharmacokineticinteractionsbetweendrugsandcannabisproductsinhumans AT estherpapaseit anoverviewofthepotentialforpharmacokineticinteractionsbetweendrugsandcannabisproductsinhumans AT dollyandreacaicedo overviewofthepotentialforpharmacokineticinteractionsbetweendrugsandcannabisproductsinhumans AT claraperezmana overviewofthepotentialforpharmacokineticinteractionsbetweendrugsandcannabisproductsinhumans AT magifarre overviewofthepotentialforpharmacokineticinteractionsbetweendrugsandcannabisproductsinhumans AT estherpapaseit overviewofthepotentialforpharmacokineticinteractionsbetweendrugsandcannabisproductsinhumans |